The revenue of Aperam in Q3 showed us lower ebitda/revenue than analysts expected. Still they managed to reduce debt and the outlook for Q4 is positive. Today a gap of -8% and it already filled the gap all the way up the opening. For now I anticipate on more upside.
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。